These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 32017532)
1. Structure-Guided Design and In-Cell Target Profiling of a Cell-Active Target Engagement Probe for PARP Inhibitors. Howard RT; Hemsley P; Petteruti P; Saunders CN; Molina Bermejo JA; Scott JS; Johannes JW; Tate EW ACS Chem Biol; 2020 Feb; 15(2):325-333. PubMed ID: 32017532 [TBL] [Abstract][Full Text] [Related]
2. Olaparib-Based Photoaffinity Probes for PARP-1 Detection in Living Cells. Voorneveld J; Florea BI; Bakkum T; Mendowicz RJ; van der Veer MS; Gagestein B; van Kasteren SI; van der Stelt M; Overkleeft HS; Filippov DV Chembiochem; 2020 Sep; 21(17):2431-2434. PubMed ID: 32282108 [TBL] [Abstract][Full Text] [Related]
3. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials. Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302 [TBL] [Abstract][Full Text] [Related]
4. Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer. Wang Z; Grosskurth SE; Cheung T; Petteruti P; Zhang J; Wang X; Wang W; Gharahdaghi F; Wu J; Su N; Howard RT; Mayo M; Widzowski D; Scott DA; Johannes JW; Lamb ML; Lawson D; Dry JR; Lyne PD; Tate EW; Zinda M; Mikule K; Fawell SE; Reimer C; Chen H Cancer Res; 2018 Dec; 78(23):6691-6702. PubMed ID: 30297535 [TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415 [TBL] [Abstract][Full Text] [Related]
6. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions. Kwon M; Jang H; Kim EH; Roh JL Cell Cycle; 2016 Nov; 15(22):3105-3114. PubMed ID: 27686740 [TBL] [Abstract][Full Text] [Related]
8. Novel anti- Chen L; Han W; Jing W; Feng M; Zhou Q; Cheng X Front Cell Infect Microbiol; 2024; 14():1414135. PubMed ID: 38863831 [TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis and Activity Evaluation of New Phthalazinone PARP Inhibitors. Huang M; Ren J; Wang Y; Chen X; Yang J; Tang T; Yang Z; Li X; Ji M; Cai J Chem Pharm Bull (Tokyo); 2021; 69(7):620-629. PubMed ID: 34193711 [TBL] [Abstract][Full Text] [Related]
10. Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib. Gravells P; Neale J; Grant E; Nathubhai A; Smith KM; James DI; Bryant HE DNA Repair (Amst); 2018 Jan; 61():25-36. PubMed ID: 29179156 [TBL] [Abstract][Full Text] [Related]
11. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors. Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019 [TBL] [Abstract][Full Text] [Related]
12. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors. Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384 [TBL] [Abstract][Full Text] [Related]
13. Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities. Lin S; Zhang L; Zhang X; Yu Z; Huang X; Xu J; Liu Y; Chen L; Wu L Bioorg Med Chem; 2020 May; 28(9):115434. PubMed ID: 32222339 [TBL] [Abstract][Full Text] [Related]
14. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function. Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892 [TBL] [Abstract][Full Text] [Related]
15. Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials. Wang L; Yang C; Xie C; Jiang J; Gao M; Fu L; Li Y; Bao X; Fu H; Lou L Cancer Sci; 2019 Mar; 110(3):1064-1075. PubMed ID: 30663191 [TBL] [Abstract][Full Text] [Related]
16. Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma. Ferrarotto R; Cardnell R; Su S; Diao L; Eterovic AK; Prieto V; Morrisson WH; Wang J; Kies MS; Glisson BS; Byers LA; Bell D Head Neck; 2018 Aug; 40(8):1676-1684. PubMed ID: 29570891 [TBL] [Abstract][Full Text] [Related]
17. Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells. McDonald ES; Mankoff J; Makvandi M; Chu W; Chu Y; Mach RH; Zeng C Biochem Biophys Res Commun; 2017 May; 486(3):788-795. PubMed ID: 28347815 [TBL] [Abstract][Full Text] [Related]
18. PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice. Ghonim MA; Pyakurel K; Ibba SV; Wang J; Rodriguez P; Al-Khami AA; Lammi MR; Kim H; Zea AH; Davis C; Okpechi S; Wyczechowska D; Al-Ghareeb K; Mansy MS; Ochoa A; Naura AS; Boulares AH Clin Sci (Lond); 2015 Dec; 129(11):951-62. PubMed ID: 26205779 [TBL] [Abstract][Full Text] [Related]
19. HMGA2 as a functional antagonist of PARP1 inhibitors in tumor cells. Hombach-Klonisch S; Kalantari F; Medapati MR; Natarajan S; Krishnan SN; Kumar-Kanojia A; Thanasupawat T; Begum F; Xu FY; Hatch GM; Los M; Klonisch T Mol Oncol; 2019 Feb; 13(2):153-170. PubMed ID: 30289618 [TBL] [Abstract][Full Text] [Related]
20. Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1). Zhang Z; Chang X; Zhang C; Zeng S; Liang M; Ma Z; Wang Z; Huang W; Shen Z J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1606-1615. PubMed ID: 32779949 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]